A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study



Status:Recruiting
Conditions:High Blood Pressure (Hypertension), Ocular
Therapuetic Areas:Cardiology / Vascular Diseases, Ophthalmology
Healthy:No
Age Range:18 - Any
Updated:8/2/2017
Start Date:July 25, 2017
End Date:February 2018
Contact:Santen Inc. Clinical Operations
Email:clinicaltrials@santeninc.com
Phone:+1 415-268-9100

Use our guide to learn which trials are right for you!

A Phase IIb, Randomized, Observer-Masked, Placebo- and Active-Controlled, Parallel-Group, Multinational and Multicenter Study Assessing the Safety and Efficacy of DE-126 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

Treatment of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop
medications has been shown to be effective in delaying or preventing the progression of
glaucoma, and it is the only proven method for reducing the risk of glaucomatous visual field
loss.

This study is being conducted to determine how well DE-126 ophthalmic solution works
(efficacy) in safely lowering IOP when dosed as topical eyedrops. This study will evaluate
the safety and efficacy of four (4) concentrations of DE-126, when compared with latanoprost
(0.005%) eye drops in patients with primary open-angle glaucoma or ocular hypertension.

The IOP will be measured at 3 different times throughout the day, over 6 total visits during
a 3-month treatment period (with up to 4 extra weeks observation if the patient must stop
taking current eye drops to lower IOP). Safety assessments will be done throughout the study,
including ocular signs and symptoms, vital signs, and clinical laboratory tests. While the
most important time-point to measure IOP in this study and evaluate efficacy will be at the
final study visit (month 3), IOP values will also be evaluated at other visits throughout the
3-month treatment period.


Inclusion Criteria:

- Provide signed written informed consent

- Diagnosis of POAG or OHT in both eyes

- Qualifying corrected visual acuity in each eye

- Qualifying central corneal thickness in each eye

- Qualifying Day 1 IOP measurement at 3 time-points in both eyes

- Qualifying Anterior chamber angle

Exclusion Criteria:

- History of ocular surgery specifically intended to lower IOP

- Subjects who cannot safely discontinue use of ocular hypotensive medications during
the wait/washout period

- Advanced glaucoma in either eye

- Any corneal abnormality or other condition interfering with or preventing reliable
Goldmann applanation tonometry

- Any ocular surgery or ocular laser treatment within 90 days prior to Visit 1
(Screening) and throughout the study in either eye

- Females who are pregnant, nursing, or planning a pregnancy
We found this trial at
13
sites
Newport Beach, California
?
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Artesia, California 90701
?
mi
from
Artesia, CA
Click here to add this to my saved trials
?
mi
from
Austin, TX
Click here to add this to my saved trials
Charlotte, North Carolina
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Fukuoka-shi, Fukuoka,
?
mi
from
Fukuoka-shi, Fukuoka,
Click here to add this to my saved trials
High Point, North Carolina 27262
?
mi
from
High Point, NC
Click here to add this to my saved trials
Largo, Florida
?
mi
from
Largo, FL
Click here to add this to my saved trials
Mission Hills, California
?
mi
from
Mission Hills, CA
Click here to add this to my saved trials
1000 Corporate Center Drive
Morrow, Georgia 30260
?
mi
from
Morrow, GA
Click here to add this to my saved trials
Petaluma, California 94954
?
mi
from
Petaluma, CA
Click here to add this to my saved trials
Rochester, New York 14618
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Roswell, Georgia 30076
?
mi
from
Roswell, GA
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials